3 Vanguard ETFs to Buy With $1,000 and Hold Forever Whether you've got a lot of money or just a little, these Vanguard ETFs will help you lay the foundation for successful long-term investing.
Tesla Hits Back At California DMV For Forcing Rebrand Of Driver Assistance Features: Report According to CNBC, Tesla in a complaint alleged that the agency “wrongfully and baselessly” labeled Tesla a “false advertiser” for its prior use of the terms Autopilot and Full Self-Driving.
KMX Stock Slumps On DOJ Settlement Over Military Personnel Vehicle Purchase The DOJ said that the settlement seeks to resolve allegations that CarMax illegally repossessed motor vehicles owned by members of the military without obtaining court orders.
Uber To Allow Parking Reservations On App With New Acquisition The acquisition is aimed at bringing parking reservations onto the Uber app powered by Spothero, the company said.
Smart Move? Institutional Investor Exits Position in This Vanguard ETF A wealth manager recently dumped all of its shares of the Vanguard Russell 1000 ETF.
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock TD Cowen analyst Joseph Thome’s new price target represents a potential upside of about 23% from AXSM’s current trading levels.
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder The company applied for approval of the gene therapy in the treatment of Glycogen Storage Disease Type Ia or Von Gierke disease.
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics.
Is Microsoft Down? Downdetector Reports Issues With Azure, Outlook, MSFT 365 Microsoft flagged that services that require Multi-Factor Authentication may return gateway timeout errors for users in the U.S.
Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost? The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website.
How Broad Market ETFs Like VTI Can Support Long-Term Portfolio Stability Diversification is overlooked by many investors, but it can be a powerful tool for building long-term wealth.
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data
Palo Alto Networks Removed From Wedbush’s ‘Best Ideas List’ — Here’s Why According to TheFly, Wedbush’s Dan Ives cited investment price discipline as the reason for the removal of PANW from the list.
Why Did ACLX Stock Surge 80% In Pre-Market Today? Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.
You Don't Need to Buy Apple Stock. Here's Why The tech giant has been a big winner for years, but there's a simple reason why many investors can leave it out of their portfolios
SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December.
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time.
Lucid Reportedly Lays Off 12% Workforce Amid Gravity SUV Ramp-Up Techcrunch reported on Friday, citing an internal memo, that the layoffs are likely to impact hundreds of employees.
GE Stock On Track To Hit All-Time High: Morgan Stanley Calls It A ‘Structural Winner’, Flags 27% Upside Morgan Stanley initiated coverage of the stock with an ‘Overweight’ rating and a price target of $425, according to The Fly.
